Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR)

Investment analysts at Canaccord Genuity Group began coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a report issued on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $8.00 price target on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 396.89% from the stock’s current price.

Separately, Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th.

Marker Therapeutics Stock Performance

MRKR opened at $1.61 on Wednesday. The stock has a fifty day moving average of $2.19 and a 200-day moving average of $2.98. Marker Therapeutics has a 12-month low of $1.35 and a 12-month high of $5.99.

Insider Activity at Marker Therapeutics

In related news, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the transaction, the insider now owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steve Elms bought 11,085 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the transaction, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC bought a new position in shares of Marker Therapeutics during the 4th quarter worth about $50,000. Invst LLC acquired a new stake in Marker Therapeutics during the third quarter valued at approximately $56,000. Northern Trust Corp grew its stake in shares of Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after purchasing an additional 21,703 shares during the period. LPL Financial LLC acquired a new position in shares of Marker Therapeutics in the 4th quarter worth approximately $248,000. Finally, Aisling Capital Management LP lifted its position in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after buying an additional 11,084 shares during the period. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.